|
| dbGaP Submitter Subject ID (ID2) | Coriell Sample ID | Consent | Control | Gender | Race | Age | Baseline Max AMD Severity | Final Max AMD Severity |
| AR2_0168 | ED149557 | General Research Use | No | Male | White | 75 | 5 - AREDS AMD Severity Scale Step 4 | 6 - AREDS AMD Severity Scale Step 6 |
| AR2_0412 | ED148328 | General Research Use | No | Male | White | 74 | 5 - AREDS AMD Severity Scale Step 3 | 7 - AREDS AMD Severity Scale Step 7 |
| AR2_1038 | ED149031 | General Research Use | No | Female | White | 65 | 5 - AREDS AMD Severity Scale Step 2 | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue |
| AR2_1100 | ED149009 | General Research Use | No | Female | White | 65 | 5 - AREDS AMD Severity Scale Step 3 | 5 - AREDS AMD Severity Scale Step 5 |
| AR2_1803 | ED148512 | General Research Use | No | Female | White | 59 | 5 - AREDS AMD Severity Scale Step 5 | 6 - AREDS AMD Severity Scale Step 6 |
| AR2_1846 | ED148829 | General Research Use | No | Female | White | 60 | 5 - AREDS AMD Severity Scale Step 5 | 6 - AREDS AMD Severity Scale Step 6 |
| AR2_2874 | ED148371 | General Research Use | No | Female | White | 61 | 5 - AREDS AMD Severity Scale Step 5 | 7 - AREDS AMD Severity Scale Step 7 |
| AR2_3239 | ED149803 | General Research Use | No | Female | White | 65 | 5 - AREDS AMD Severity Scale Step 5 | 10 - Central GA |
| AR2_3871 | ED149086 | General Research Use | No | Female | White | 67 | 5 - AREDS AMD Severity Scale Step 5 | 8 - AREDS AMD Severity Scale Step 8 |
| AR2_3999 | ED148126 | General Research Use | No | Female | White | 53 | 5 - AREDS AMD Severity Scale Step 5 | 6 - AREDS AMD Severity Scale Step 6 |
| AR2_4154 | ED148898 | General Research Use | No | Male | White | 79 | 5 - AREDS AMD Severity Scale Step 5 | 6 - AREDS AMD Severity Scale Step 6 |
| AR2_0064 | ED149777 | General Research Use | No | Female | White | 70 | 5 - AREDS AMD Severity Scale Step 5 | 7 - AREDS AMD Severity Scale Step 7 |
| AR2_0365 | ED149387 | General Research Use | No | Female | White | 71 | 5 - AREDS AMD Severity Scale Step 1 | 3 - AREDS AMD Severity Scale Step 3 |
| AR2_0384 | ED148389 | General Research Use | No | Male | White | 82 | 5 - AREDS AMD Severity Scale Step 4 | 6 - AREDS AMD Severity Scale Step 6 |
| AR2_1036 | ED148531 | General Research Use | No | Female | White | 63 | 5 - AREDS AMD Severity Scale Step 5 | 7 - AREDS AMD Severity Scale Step 7 |
| AR2_2170 | ED149446 | General Research Use | No | Female | White | 72 | 5 - AREDS AMD Severity Scale Step 5 | 7 - AREDS AMD Severity Scale Step 7 |
| AR2_3151 | ED148056 | General Research Use | No | Male | White | 65 | 5 - AREDS AMD Severity Scale Step 5 | 7 - AREDS AMD Severity Scale Step 7 |
| AR2_1328 | ED149468 | General Research Use | No | Female | White | 58 | 5 - AREDS AMD Severity Scale Step 5 | 7 - AREDS AMD Severity Scale Step 7 |
| AR2_1361 | ED148167 | General Research Use | No | Female | White | 73 | 5 - AREDS AMD Severity Scale Step 5 | 11b - Neovascular AMD with end-stage disease (e.g., definite disciform scar, or photocoagulation scar), or two or more of the following five characteristics of neovascular AMD: SSR detachment, PED, subretinal/sub-RPE hemorrhage, hard exudate, or fibrous tissue |
| AR2_1750 | ED148986 | General Research Use | No | Female | White | 77 | 5 - AREDS AMD Severity Scale Step 3 | 7 - AREDS AMD Severity Scale Step 7 |